T2 Biosystems, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
T2 Biosystems' Q3 2024 results show increased product revenue but ongoing losses and substantial doubt about the company's ability to continue as a going concern.
OTC.Pink
T2 Biosystems reported its Q2 2024 financial results, highlighting ongoing losses and concerns about its ability to continue as a going concern.
OTC.Pink
T2 Biosystems reported a net loss of $13.5 million for the first quarter of 2024, while also expressing substantial doubt about its ability to continue as a going concern.